AGI

AMD invests up to $5 billion in Anthropic for AI infrastructure, agreeing to supply tens of billions of dollars in AMD-powered AI systems, including Instinct MI450 accelerators. This strategic partnership, alongside similar deals with OpenAI and Meta, highlights AMD’s aggressive push to capture the AI market by integrating its technology and financial backing into large-scale AI deployments, positioning itself as a key hardware and investment partner for leading AI developers.

SenseTime launches the “Galaxy Project” with nearly 20 partners to expand China’s AI chip infrastructure. The initiative focuses on a closed-loop system integrating chip development, ecosystem partnerships, and AI computing deployment. Key strategies include improving token processing efficiency, enabling multi-chip adaptability, and pioneering energy efficiency metrics. The project also explores advanced computing like space and quantum. While ambitious, claims of performance and cost-effectiveness require independent verification.

Google has launched Gemini 3.6 Flash and 3.5 Flash-Lite, AI models designed to drastically cut latency and token costs for enterprise AI agents. Gemini 3.6 Flash optimizes coding and multimodal reasoning with reduced token output and improved benchmark scores. Gemini 3.5 Flash-Lite targets high-volume, low-latency tasks, offering extreme cost-efficiency. A specialized variant, Gemini 3.5 Flash Cyber, is available for government entities and partners for code vulnerability remediation. These models aim to enhance the economics and efficiency of deploying autonomous AI agents.

Generative AI tools, designed to maximize user engagement, often hinder productivity by encouraging prolonged interaction over task completion. This “variable reward loop” leads to fragmented focus and cognitive fatigue. While on-paper efficiency gains are reported, real-world application shows AI intensifying work and increasing workload. Professionals must protect deep work periods by setting boundaries and limiting AI session durations to leverage AI’s benefits without sacrificing concentration.

Bristol Myers Squibb is enhancing its drug discovery capabilities by acquiring NVIDIA’s DGX SuperPOD with Vera Rubin architecture. This investment provides advanced computing power for training AI models, predicting compound behavior, and accelerating therapeutic innovation. The system will democratize access to AI tools for researchers worldwide, significantly streamlining the R&D pipeline and enabling faster, more efficient evaluation of potential drug candidates.

US policy debates around Chinese open-weight AI models like Kimi K3 are creating uncertainty for global businesses. While concerns exist about security and potential regulatory pressure, the economic advantages of these models are significant. Enterprises must consider the long-term accessibility and integration costs of these models, as global cloud providers may be influenced by US policy, impacting availability and requiring potential self-hosting solutions.

US public health departments are piloting generative AI tools through the PULSE initiative, a collaboration involving CHAI, OpenAI, Anthropic, and Accenture. Ten jurisdictions will test AI for biosurveillance, social determinants of health, operational efficiency, public communications, and clinical data retrieval. The program aims to create practical implementation guides, focusing on trust, governance, and execution, to prepare agencies for AI adoption.

Moonshot AI’s Kimi K3, a 2.8 trillion-parameter open-weight model, utilizes “mixture-of-experts” and quantization-aware training to optimize memory over compute, potentially circumventing U.S. restrictions. This approach allows it to function with reduced computational demands, though memory requirements remain substantial. Despite impressive performance in specific benchmarks, Kimi K3 still trails leading models in overall capabilities. Its release on July 27th will offer a significant opportunity to assess its impact on the open-weight model landscape.

Bunkerhill Health raised $55 million in Series B funding to scale its agentic AI platform, Carebricks. The funding will accelerate the deployment of AI solutions within hospitals, addressing the gap between AI efficacy in research and real-world clinical integration. Carebricks enables health systems to build custom AI agents for various clinical and administrative tasks, as demonstrated by successful implementations at the University of Texas Medical Branch.

Google DeepMind and Isomorphic Labs launched a bioresilience program using AI to enhance biosecurity and prevent misuse. The initiative involves over 15 partnerships, focusing on preventing misuse, detecting threats, and responding to outbreaks. They are developing AI safeguards, improving DNA synthesis screening, and advancing cost-effective sequencing. AlphaFold is aiding countermeasure development, with Isomorphic Labs ready to deploy its drug design engine during outbreaks. The program aligns with legislative proposals to strengthen biosecurity frameworks.